ShK-186: Phase Ib complete enrollment

Kineta completed enrollment in a double-blind, placebo-controlled, Canadian Phase Ib trial evaluating biweekly subcutaneous ShK-186 for 4 weeks. Kineta licensed the compound from Airmid in 2009 (see B...